Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05946551 · ClinicalTrials.gov registry record · Phase 3
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
A Phase 3 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT05946551 is a Phase 3 study that was terminated before completion, run by Emory University. The registered enrollment target is 5 participants.
The verdict
NCT05946551, a Phase 3 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR) positive test and/or medical records from a healthcare provider that coincides with the diagnosis of long-COVID.
Interventions
- DRUG Famotidine
- DRUG Cetirizine
- DRUG Cetirizine Placebo
- DRUG Famotidine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05946551
The ClinicalTrials.gov registry entry for NCT05946551 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Famotidine is the first listed.
NCT05946551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05946551 about?
NCT05946551 is a clinical study titled "Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial". The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Polymer...
What is the current status of trial NCT05946551?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2024-03-08. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05946551?
The interventions under investigation include: Famotidine (DRUG), Cetirizine (DRUG), Cetirizine Placebo (DRUG), Famotidine Placebo (DRUG).
Who is sponsoring clinical trial NCT05946551?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.